A massive international clinical study published in May 2026 suggests beta blockers may provide no meaningful benefit and could pose risks for many patients after heart attacks, potentially upending four decades of standard cardiology practice.
Researchers analyzed outcomes across diverse health systems, finding that routine long-term beta blocker use did not significantly reduce mortality or major cardiovascular events in the modern treatment era when paired with current revascularization and medication protocols.
Beta blockers slow heart rate and reduce blood pressure, and guidelines have recommended them post-myocardial infarction since large trials in the late twentieth century. The new evidence indicates improvements in acute care may have diminished the drugs’ incremental value for broad patient groups.
Some subgroups with heart failure or arrhythmia indications may still benefit, investigators said, warning against abrupt discontinuation without physician supervision. Cardiology societies are expected to review guideline updates as peer commentary evaluates the trial’s methodology and external validity.
Patients currently prescribed beta blockers after heart attacks should consult clinicians before changing regimens. The findings could shift prescribing patterns affecting millions worldwide and influence insurance formularies.
Publication in a major journal triggered immediate debate at cardiovascular conferences convening during spring 2026.
Hospital cardiology departments said patients should continue prescribed beta blocker regimens until specialists review individual records in light of the newly published international evidence.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/top/science/